Bipolar Disorder in Tuberous Sclerosis Complex: A Case Report

Why It Matters

The association signals that clinicians should screen TSC patients for mood disorders, as timely treatment can improve neurological and systemic outcomes. Recognizing this link also guides resource allocation for integrated neuropsychiatric services.

Key Takeaways

• Bipolar disorder rarely co-occurs with tuberous sclerosis (5 cases)
• Early neuroimaging crucial for diagnosing TSC with psychiatric symptoms
• Multidisciplinary care improves outcomes for TSC patients with mood disorders
• Cortical tubers appear hyperintense on T2/FLAIR MRI sequences
• Prompt psychiatric treatment reduces long‑term complications in TSC

Pulse Analysis

Tuberous sclerosis complex (TSC) affects roughly one in 6,000 births and manifests through benign growths in the brain, skin, kidneys, and heart. While seizures, autism spectrum disorder, and anxiety dominate the neuropsychiatric profile, mood disorders such as bipolar disorder remain exceedingly rare, with only five documented cases before this report. This scarcity can delay recognition, as clinicians often prioritize more common TSC complications. Understanding the full spectrum of psychiatric comorbidities is essential for comprehensive patient care and for informing insurers and providers about the breadth of services required.

Advanced magnetic resonance imaging (MRI) techniques are pivotal in differentiating TSC lesions from other cortical abnormalities. Hyperintense signals on T2‑weighted and FLAIR sequences, coupled with susceptibility‑weighted blooming, reliably identify cortical tubers, while subependymal nodules appear hypointense on T2. When these radiologic hallmarks appear alongside atypical affective symptoms, a coordinated diagnostic pathway—integrating neurology, psychiatry, and dermatology—can expedite treatment initiation. Early pharmacologic intervention for bipolar symptoms, combined with seizure control, reduces the risk of cognitive decline and systemic complications, underscoring the value of multidisciplinary clinics.

From a healthcare market perspective, this case highlights growing demand for integrated neuropsychiatric services and specialized imaging platforms. Hospitals investing in high‑resolution MRI suites and cross‑specialty care teams can capture a niche segment of patients with complex neurocutaneous disorders. Moreover, pharmaceutical firms developing mood‑stabilizing agents may find an underserved population within the TSC community, presenting opportunities for targeted clinical trials and compassionate‑use programs. Raising clinician awareness through case reports and continuing‑medical‑education initiatives can therefore drive both better patient outcomes and strategic business growth in the neuro‑oncology and psychiatric sectors.